Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms

The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.

Authors

Kylie N. Barnes (ORCID: https://orcid.org/0000-0002-1060-5164)
Jordan M. Rowe
Ian Coffman

Institutions

University of Missouri–Kansas City (US)

Publication Details

Journal: Annals of Pharmacotherapy
Published: 2026-03-23
DOI: https://doi.org/10.1177/10600280261426643
Primary Topic: Menopause: Health Impacts and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms

Kylie N. Barnes, Jordan M. Rowe, Ian Coffman

Mar 23, 2026

Annals of Pharmacotherapy

Menopause: Health Impacts and Treatments

article

Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms

Kylie N. Barnes, Jordan M. Rowe, Ian Coffman

March 23, 2026article en

Abstract

Annals of Pharmacotherapy

University of Missouri–Kansas City (US)

Zero hunger

Openalex Percentile: Top 14%

Menopause: Health Impacts and Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms — Kylie N. Barnes, Jordan M. Rowe, et al. · Annals of Pharmacotherapy (2026) | TGRS Research Map | TGRS